In this episode, endocrinologist Margarita Ochoa-Maya, MD, speaks with endocrinologist Katherine Arakay, MD, of the University of California, Los Angeles (UCLA), about clinical trials for rare endocrine disorders. The conversation examines clinical trials from three perspectives: patients, clinical researchers, and sponsors.
What are Clinical Trials?
In simple terms, a clinical trial is a research study involving people that helps doctors and scientists learn whether a treatment works, how safe it is, and whether it could improve people’s health.
For example, researchers may discover a new medication that could help people with a rare hormonal condition.
Before that medication becomes widely available, scientists need to study it carefully in people to understand its potential benefits and risks.
That’s what clinical trials help us do.
Importantly, clinical trials aren’t always reserved for people with no treatment options. Many studies investigate treatments for patients who haven’t responded adequately to existing medications or explore new approaches to care. That’s an important distinction, because many patients hear the words “clinical trial” and immediately assume their current treatment has failed.
Clinical trials are not simply a last resort. They’re an opportunity to learn about research, contribute to medical progress, and explore potential treatment options at different stages of their disease journey.
Patients’ Perspective
Patients enroll in a clinical trial for a variety of reasons. Some want to access investigational therapies, especially when existing treatments don’t adequately address their needs.
Others are motivated by the opportunity to contribute to science. This is especially meaningful in rare diseases. Patients often recognize that the knowledge gained from their participation could help others living with the same condition.
And for many, improving quality of life is a major motivation. They want treatments that don’t just improve laboratory results but also help them feel better and function better in everyday life.
Of course, participating in a clinical trial doesn’t guarantee an individual medical benefit. However, they are designed to keep the patient as safe as possible and allow them to leave the trial at any time. Clinical trials follow established ethical and scientific standards designed to protect participants. Before a study begins, its design is reviewed by an independent ethics committee, often called an Institutional Review Board, or IRB. During the study, researchers carefully monitor participants for potential side effects and safety concerns. With that said, clinical trials involve uncertainty, particularly when studying new treatments.
That’s why informed consent is important. Patients should receive clear information about potential risks, possible benefits, and available alternatives before deciding whether to participate. And ultimately, the decision always belongs to the patient.
In addition to safety (and treatment concerns), there are also practical challenges that can be concerning to patients, such as travel, time away from work, childcare, and the financial burden of participating, which can all influence a patient’s decision.
Some clinical trials offer travel reimbursement, remote visits, or the option to complete certain laboratory tests closer to home. Not every study offers these options, but patients should feel comfortable asking what support may be available. Understanding these practical commitments upfront can help patients decide whether participation is realistic for them.
Clinical Researchers’ Perspective
One of the biggest challenges facing clinical research centers is patient recruitment. By definition, rare diseases affect relatively small populations. Those patients may be spread across different cities, states, or countries. Some receive their medical care at large academic institutions, while others are followed by endocrinologists in community practices. As a result, patients who could potentially benefit from learning about a clinical trial may never hear about it.
That’s why strengthening relationships between research centers and community physicians is so important. Patient advocacy organizations also play an important role in increasing awareness and connecting people with research programs.
Another challenge is eligibility. A patient may find a clinical trial that sounds appropriate for their condition, only to learn they don’t qualify.
Every clinical trial has requirements that determine who can participate. Those requirements may include a specific diagnosis, laboratory results, age range, prior treatments, or other medical conditions. They’re designed to help protect patient safety and ensure researchers can answer the scientific question the study is investigating.
But in rare diseases, eligibility requirements can make recruitment particularly challenging because the patient population is already small.
Another challenge facing clinical research centers is the complexity of these trials. Conducting a clinical trial requires a team of physicians, research coordinators, nurses, pharmacists, and other professionals. They manage study visits, laboratory testing, safety monitoring, documentation, and regulatory requirements.
And then there’s the challenge of keeping patients engaged throughout the study. Many clinical trials last months or sometimes years. Research centers have to make sure participants feel supported and understand what to expect throughout that period. Their goal is to make research more accessible, less burdensome, and genuinely patient-centered.
The Sponsors’ Perspective
A sponsor is the organization or individual responsible for initiating and overseeing a clinical trial. In drug development, that’s often a pharmaceutical or biotechnology company, although academic institutions and individual investigators can also sponsor studies.
The sponsor is responsible for organizing the research, developing the study protocol, arranging appropriate oversight, and ensuring the study is conducted according to applicable requirements. Ultimately, the sponsor is trying to answer important scientific questions about a potential treatment.
Sponsors have to design studies that can generate reliable scientific evidence while recognizing that the population may be very small. This requires careful decisions about eligibility criteria, study duration, assessments, and how treatment outcomes will be measured.
There’s always a balance between scientific rigor and what is realistically feasible for patients and research sites. Even a scientifically excellent trial may be difficult to recruit and retain patients if participation places too much burden on patients.
That’s why sponsors need to collaborate early with clinicians, research centers, and patient communities: to design trials that maintain scientific quality while minimizing unnecessary burden.
Summarizing all three perspectives, it is clear that clinical trials are a welcome necessity to improve care for patients with rare endocrine disorders. Clinical trials are not simply a last resort. They are how medical innovation moves forward.
Listen to previous episodes of Rare Endocrine Exchange at https://checkrare.com/multimedia/rare-endocrine-exchange/
